Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 842 clinical trials
Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors

This trial studies the benefits of an exercise and diet counseling program in improving quality of life in stage I-III breast cancer survivors. Exercise and diet counseling may help improve weight loss and relevant clinical and patient-reported outcomes in overweight or obese breast cancer survivors.

cancer
prognostic stage iiic breast cancer ajcc v8
prognostic stage iib breast cancer ajcc v8
anatomic stage iiia breast cancer ajcc v8
stage iib breast cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

traditional chinese medicine
cancer
adjuvant
progesterone
epidermal growth factor receptor
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

cancer
capecitabine
epidermal growth factor receptor
hormone therapy
growth factor
  • 0 views
  • 16 Feb, 2024
  • 16 locations
LYT-100 in Healthy Volunteers and BCRL

Part 3 is a trial of up to 6-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast carcinoma patients with secondary lymphoedema

carcinoma
secondary lymphedema
nipple reconstruction
cancer
adjuvant
  • 0 views
  • 16 Feb, 2024
  • 1 location
Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer

It is not yet known what level of complications x-ray therapy or proton beam radiation therapy have in treating patients with breast cancer.

x-rays
cancer
breast-conserving surgery
prognostic stage iiic breast cancer ajcc v8
prognostic stage iib breast cancer ajcc v8
  • 0 views
  • 05 Jan, 2021
Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies

The main purpose of this study is to evaluate the impact of food supplements (herbal remedies) on sign and symptoms induced by cancer therapies: Nettle will be administered for improvement of anemia and fatigue; Peppermint will be administered for improvement of nausea. Secondary aims of the trial are to evaluate …

vomit
parp inhibitor
adjuvant
cancer
immunostimulant
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

cancer
solid tumor
hair thinning
hormone therapy
health screening
  • 0 views
  • 16 Feb, 2024
  • 5 locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

cancer
stage iv breast cancer
HER2
epidermal growth factor
epidermal growth factor receptor
  • 0 views
  • 16 Feb, 2024
  • 7 locations
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC

cancer
serum pregnancy test
axillary lymph node dissection
serum bilirubin level
camrelizumab
  • 0 views
  • 05 Aug, 2020
Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of ZW25 in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ) adenocarcinoma

cancer
adenocarcinoma
epidermal growth factor receptor
growth factor
recurrent disease
  • 0 views
  • 16 Feb, 2024
  • 12 locations